Showing 2421-2430 of 5909 results for "".
- Aviceda Announces 3 Presentations on AVD-104, its Lead Glyco-mimetic Nanoparticle, As Treatment for GA at ARVOhttps://modernod.com/news/aviceda-announces-3-presentations-on-avd-104-its-lead-glyco-mimetic-nanoparticle-as-treatment-for-ga-at-arvo/2481507/Aviceda Therapeutics announced its upcoming oral and poster presentations at the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans, April 23-27, 2023. Detailed results from each of these three studies will be reported at the conference.
- Pixium Vision Announces FDA Breakthrough Device Designation for the Prima System in Dry AMDhttps://modernod.com/news/pixium-vision-announces-fda-breakthrough-device-designation-for-the-prima-system-in-dry-amd/2481505/The FDA has granted Breakthrough Device Designation to Pixium Vision's Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision implanted in human patients with atrophic dry age-related macular
- Cellusion Announces First Patient Transplanted iPSC-Derived Corneal Endothelial Cell Substitute (CLS001)https://modernod.com/news/cellusion-announces-first-patient-transplanted-ipsc-derived-corneal-endothelial-cell-substitute-cls001/2481493/An iPS cell-derived corneal endothelial cell substitute (CLS001) was transplanted to the first patient, according to Cellusion. Research collaborator, Shigeto Shimmura, MD, PhD, Professor of Fujita Health University and Keio University in Japan, provided details of the procedure&nb
- Cognition Therapeutics Announces Development Plans for Oral CT1812 in GA Secondary to Dry AMDhttps://modernod.com/news/cognition-therapeutics-announces-development-plans-for-oral-ct1812-in-ga-secondary-to-dry-amd/2481472/Cognition Therapeutics announced that its investigational new drug (IND) application for CT1812 for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) has been cleared by the FDA. Cognition plans to initiate the phase 2 MAGNIFY trial of its oral drug candidate&nb
- New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSDhttps://modernod.com/news/new-analysis-of-mri-findings-show-uplizna-reduced-the-formation-of-asymptomatic-optic-nerve-lesions-in-people-with-nmosd/2481467/Horizon Therapeutics announced the presentation of new MRI imaging data from the phase 3 clinical trial showing Uplizna (inebilizumab-cdon) reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with Neuromyelitis Optica Spectrum Disorder (NMOSD). These findin
- Study: Iyuzeh Demonstrated Similar IOP Lowering Efficacy with a Favorable Safety Profile when Compared to Xalatanhttps://modernod.com/news/study-iyuzeh-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-glaucoma-patients/2481450/Thea Pharma announced the presentation of phase 3 data on Iyuzeh (latanoprost ophthalmic solution 0.005%) by Jason Bacharach, MD, at the 2023 American Glaucoma Society (AGS) Annual Meeting. The large, pivotal clinical trial demonstrated comparable efficacy of preservative-free 
- Grifols Enters Into Global Collaboration and Licensing Agreement with Selagine to Develop Immunoglobulin Eye Drops to Treat Dry Eye Diseasehttps://modernod.com/news/grifols-enters-into-global-collaboration-and-licensing-agreement-with-selagine-to-develop-immunoglobulin-eye-drops-to-treat-dry-eye-disease/2481446/Spanish pharma company Grifols announced a global collaboration and licensing agreement with Selagine to treat dry eye disease (DED) with immunoglobulin eye drops. Financial terms of the deal were not disclosed. The potential immunoglobulin treatment would be G
- New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels From Childhood Vaccineshttps://modernod.com/news/new-data-suggest-uplinza-for-the-treatment-of-nmosd-did-not-increase-the-risk-of-covid-19-or-reduce-antibody-levels-from-childhood-vaccines/2481438/Horizon Therapeutics announced new data suggest Uplinza does not increase susceptibility to COVID infection or deplete childhood vaccine-generated antibodies. Uplinza is the first and only B-cell-depleting monotherapy approved by the FDA and the European Commission for the tre
- EyePoint and Rallybio Partner to Evaluate Inhibitor of Complement Component 5 and Durasert Technology for Intraocular Delivery in GAhttps://modernod.com/news/eyepoint-and-rallybio-partner-to-evaluate-inhibitor-of-complement-component-5-and-durasert-technology-for-intraocular-delivery-in-ga/2481435/EyePoint Pharmaceuticals and Rallybio announced a research collaboration aimed at evaluating sustained delivery of Rallybio’s inhibitor of complement component 5 (C5) using EyePoint’s proprietary Durasert technology for sustained intraocular drug delivery. The initial focus
- Study: Low Brain Pressure Could be a Risk Factor for Developing Glaucomahttps://modernod.com/news/study-low-brain-pressure-could-be-a-risk-factor-for-developing-glaucoma/2481431/An international team of researchers led by Lithuanian scientists provide additional evidence that intracranial pressure plays an important role in normal-tension glaucoma, which accounts for up to 50 percent of all glaucoma cases. A recent clinical